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Abstract
Background: Eighty per cent of UK women have at least one baby, making pregnancy an opportunity to help
women stop smoking before their health is irreparably compromised. Smoking cessation during pregnancy helps
protect infants from miscarriage, still birth, low birth weight, asthma, attention deficit disorder and adult
cardiovascular disease. UK national guidelines highlight lack of evidence for effectiveness of financial incentives to
help pregnant smokers quit. This includes a research recommendation: within a UK context, are incentives an
acceptable, effective and cost-effective way to help pregnant women who smoke to quit?
Methods: The Cessation in Pregnancy Incentives Trial (CPIT) III is a pragmatic, 42-month, multi-centre, parallel-
group, individually randomised controlled superiority trial of the effect on smoking status of adding to usual Stop
Smoking Services (SSS) support, the offer of up to £400 of financial voucher incentives, compared with usual
support alone, to quit smoking during pregnancy.
Participants (n = 940) are pregnant smokers (age > 16 years, < 24 weeks pregnant, English speaking), who consent
via telephone to take part and are willing to be followed-up in late pregnancy and 6months after birth.
The primary outcome is cotinine/anabasine-validated abstinence from smoking in late pregnancy. Secondary
outcomes include engagement with SSS, quit rates at 4 weeks from agreed quit date and 6months after birth, and
birth weight. Outcomes will be analysed by intention to treat, and regression models will be used to compare
treatment effects on outcomes. A meta-analysis will include data from the feasibility study in Glasgow. An
economic evaluation will assess cost-effectiveness from a UK NHS perspective. Process evaluation using a case-
study approach will identify opportunities to improve recruitment and learning for future implementation.
Research questions include: what is the therapeutic efficacy of incentives; are incentives cost-effective; and what are
the potential facilitators and barriers to implementing incentives in different parts of the UK?
Discussion: This phase III trial in Scotland, England and Northern Ireland follows a successful phase II trial in
Glasgow, UK. The participating sites have diverse SSS that represent most cessation services in the UK and serve
demographically varied populations. If found to be acceptable and cost-effective, this trial could demonstrate that
financial incentives are effective and transferable to most UK SSS for pregnant women.
Trial registration: Current Controlled Trials, ISRCTN15236311. Registered on 9 October 2017.
Keywords: Intervention, Randomised controlled trial, Maternal and child health, Outcomes, Pregnancy, Prevention,
Smoking cessation, Financial incentives
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Background and aims
Tobacco smoking is the leading preventable cause of
death in the UK [1]. Individuals who give up by age 40
years (during childbearing years) avoid much of the
morbidity and early mortality of continued smoking [2];
for example, lung cancer risk is reduced to two times
that of never smokers compared with 16 times for life-
long smokers. Around 80% of UK women have at least
one baby [3] so an effective intervention will eventually
reach most women who smoke. Stopping smoking dur-
ing pregnancy also reduces the likelihood of the children
themselves becoming smokers [4], thus reducing future
cancer risk.
Three hundred fifty UK still births each year [5] and a
third of babies born small for gestational age are attrib-
utable to smoking during pregnancy. One-fifth of the
125,000 spontaneous miscarriages that occur each year
in the UK [6], which cause 42,000 hospital admissions
[7], are also associated with smoking during pregnancy.
Compared with non-smokers, the relative risk of spon-
taneous miscarriage is 1.2 [8]. If causality was accepted,
this 20% increase in risk would mean that 5000 spontan-
eous miscarriages and 2000 hospital admissions in the
UK each year would be attributable to smoking during
pregnancy.
Twenty per cent of sudden unexpected deaths in in-
fancy and 9% of premature births are attributable to
maternal smoking, as are 10% of admissions for bron-
chiolitis, one of the most common reasons why infants
are admitted to hospital, and 7% of admissions for re-
spiratory infection and asthma [9]. Perhaps, surprisingly,
12% of the rare but devastating occurrence of bacterial
meningitis is attributable to maternal smoking [9], as are
increases in attention deficit disorder [10] and learning
difficulties [11] in children, adding substantial costs to
health and social care services [12].
Prevalence and available support for stopping smoking in
pregnancy
UK pregnancy smoking rates remain high. One in four
women smoke for part of their pregnancy and one in
eight smoke throughout [13]. Stop Smoking Services
(SSS) usually offer counselling plus free nicotine replace-
ment therapy (NRT); however, only 10% of pregnant
smokers use these services and as few as 3% stop smok-
ing [14]. Effective approaches are limited. New interven-
tions are needed to increase engagement with SSS,
encourage uptake, support quit attempts and produce
better outcomes [15].
Stop smoking support
Stop smoking support is freely available to pregnant
women throughout the UK. Models of support differ,
however, depending on where the women live. In
general, two main types of support are offered which
can be described as ‘specialist’ (just for pregnant women)
or ‘generic’ (for all smokers including pregnant women).
Within this framework, support offered commonly in-
cludes: individual/group support provided by specially
trained advisers who may be nurses or midwives; sup-
port provided in the hospital setting, women’s homes or
another mutually acceptable venue; at least one face-to-
face counselling session with follow-up support, often by
telephone, to 12 weeks after a quit date is set; and advice
on use of NRT utilising various models of prescribing
(e.g. nurse/GP prescribing/pharmacy).
The National Institute of Health and Care Excellence
(NICE)—PH26 Smoking: stopping in pregnancy and
after childbirth [15]—published comprehensive guidance
in 2010 regarding services that should be provided to
pregnant smokers.
Scientific premise for the trial
The rationale for incentives is that they can stimulate
behaviour change through providing an immediate re-
ward for changes in health behaviours (e.g. smoking ces-
sation), which is likely to be more motivating to people
than more distal rewards such as health improvements.
For smokers who quit, the saving of not buying ciga-
rettes provides continued ‘value’ long after incentives
have stopped. Despite the unborn child having no choice
regarding tobacco exposure, the ‘extra’ cost of incentives
is a deterrent for policy-makers and planners and is linked
to a societal moral judgement of ‘rewarding bad habits’
[16, 17]. However, public opinion towards financial incen-
tives is mixed, and public acceptability increases with ef-
fectiveness [17, 18]. This study can justify the use of
financial incentives by providing evidence to show
whether this upstream preventive intervention [19, 20]
can be cost-effective and much cheaper than trying to
cure smoking-related conditions downstream.
Evidence for use of financial incentives for stopping
smoking during pregnancy
Published research using financial incentives for smok-
ing cessation during pregnancy is limited to single-
centre trials; however, as reported in two recent
Cochrane reviews [21, 22], together they add up to a
body of work indicating a beneficial effect that is likely
to be cost-effective [23]. Combining data from nine trials
of 2273 pregnant women, the 2019 review by Notley
et al. [21] concluded that there is moderately certain evi-
dence that women in the incentives groups were more
likely to stop smoking than those in the control groups,
both at the end of the pregnancy and after the birth of
the baby—the RR at longest follow-up (up to 24 weeks
post-partum) was 2.38 (95% CI 1.54 to 3.69; N = 2273;
I
2 = 41%), in favour of incentives. The 2017 review by
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Chamberlain et al. [22] reported that high-quality evi-
dence suggests that incentive-based interventions are ef-
fective when compared with an alternative (non-
contingent incentive) intervention (four studies; RR 2.36,
95% CI 1.36 to 4.09). Pooled effects were not calculable,
however, for comparisons with usual care or less inten-
sive interventions (substantial heterogeneity, I2 = 93%).
This body of research is still not sufficient to overcome
concerns put forward by policy-makers regarding finan-
cial incentive payments [17] or to fully answer the first
research question put forward by the NICE [15]: ‘Within a
UK context, are incentives an acceptable, effective and cost-
effective way to help women who smoke to quit the habit
when they are pregnant or after they have recently given
birth? Compared with current services, do they attract
more women who smoke, do they lead to more of them
completing the stop-smoking programme and do more of
them quit for good? What level and type of incentive works
best and are there any unintended consequences?’
To start to address these research questions in a UK
context, our previous large (n = 612) single-centre feasi-
bility trial in Glasgow, UK [24] added financial incentives
to usual SSS care and compared outcomes with usual
care alone. Smokers routinely identified at first maternity
care visit were individually randomised to receive either
usual SSS support only or the same support with the
offer of financial voucher incentives. The first three
vouchers were contingent on engagement with SSS. The
last voucher (£200) could be earned by stopping without
SSS support. Twenty-three per cent quit with the offer
of usual care plus incentives (up to £400) and 9% with
the offer of usual care alone (p < 0.001). A novel embed-
ded health economic evaluation indicated that the inter-
vention was highly cost-effective [23].
Need for a further trial
The context within which incentives are offered is im-
portant. Socio-demographic, geographic and organisa-
tion differences may affect future transferability of the
intervention and the potential to implement a sustain-
able intervention in the long term [25, 26]. Adding in-
centives to a range of SSS models in different areas of
the UK serving varied population groups needs to be
tested before clear recommendations can be made.
In addition, further evidence is required to inform the
cost-effectiveness debate of incentive-based schemes.
The economic analysis from our feasibility trial [23] in-
dicated relapse post-partum was the biggest area of un-
certainty. Six months is the recommended period to
measure long-term abstinence [27], as those abstinent at
this time point tend to remain smoke-free in the long
term [28].
A pivotal phase III multi-centre UK trial that includes
cessation outcomes to 6 months after birth is therefore
required to be able to recommend changes in policy and
practice [15], and thus for SSS funders (such as the NHS
or local government in the UK) to consider this ap-
proach to smoking cessation as part of mainstream
services.
The proposed study will assess whether promising
feasibility trial findings [24] can be transferred to other
UK sites with different SSS configurations and popula-
tion groups. If found to be effective and cost-effective in
this multi-site trial, the simple novel ‘bolt-on’ nature of
the intervention will make the trial results generalisable
to a wide range of SSS and population groups, and will
allow easier transfer of the intervention to other SSS
within the UK and other parts of the world.
Objectives
This RCT will examine, within a range of usual care
pathways, the effectiveness and cost-effectiveness of fi-
nancial voucher incentives when offered in addition to
usual SSS support, to encourage women to attend SSS
and set a quit date, to quit smoking and be abstinent to-
wards the end of pregnancy and at 6 months after birth.
The primary objective is to determine whether the
offer of financial voucher incentives in addition to usual
SSS support leads to a doubling of the smoking cessation
rate by the end of pregnancy.
Secondary objectives are as follows:
 To compare quit rates at 4 weeks post quit date and
6 months after birth between women offered
incentives and those receiving usual SSS care only
 To assess, from an NHS perspective, whether
financial incentives are cost-effective in terms of cost
per quitter (at birth and 6 months post-partum) and
per quality-adjusted life year gained
 To identify the effect of differences in SSS and
demographic diversity of pregnant smokers on the
effectiveness, cost-effectiveness and transferability of
financial voucher incentives
 To explore the barriers and facilitators to trial
recruitment, retention and implementation in
different areas
Trial design
This study is a pragmatic, 42-month, multi-centre, parallel-
group, single-blinded, individually randomised controlled
superiority trial with 1:1 allocation designed to assess
whether the addition of financial incentives to usual SSS
helps pregnant women to stop smoking. In addition, an
economic evaluation from a UK NHS perspective will as-
sess cost-effectiveness of offering financial incentives added
to usual SSS; a mixed-methods theory-driven [29, 30]
process evaluation will examine barriers and facilitators to
trial enrolment and future implementation of incentives in
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a range of contexts; and data from the feasibility trial centre
in Glasgow [24], a deprived inner city, will also be analysed
in an a priori meta-analysis.
An overview of the trial design is illustrated in Fig. 1.
Methods
This protocol is reported according to the 2013 SPIRIT
Guidelines [31].
Study setting
Women will be recruited from SSS serving maternity hos-
pitals in three of the four UK nations—Scotland, England
and Northern Ireland. Participating sites include a de-
prived city, a deprived post-industrial suburban and rural
area, a provincial city, two provincial towns, a deprived
coastal city and a rural area. Each of these sites have dif-
ferent SSS configurations offering their own care pathway
within the framework of the UK NICE guidance [15].
These include NHS/local authority-run services, generic/
specialist pregnancy services, midwifery/SSS advisor-led
services and opt-in/opt-out services, and represent most
UK usual care pathways for smoking cessation in preg-
nancy. Each of the sites have between 1000 and 6000 de-
liveries per annum. The diversity of sites thus
Fig. 1 Overview of the trial design and flow of participants through the study. *CO = expired carbon monoxide. CO validated quit = CO less than
or equal to 5 ppm (site dependent to dovetail with local SSS cut-off point)
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incorporates organisational differences and facilitates re-
cruitment of a mix of women from different geographic
and socio-economic backgrounds.
Eligibility criteria
Eligible women for the trial are those who: are aged 16
years or over; are pregnant for less than 24 weeks gesta-
tion at maternity booking, or if not yet had their first
antenatal appointment, less than 24 weeks gestation at
time of consent; self-report as current smokers (at least
one cigarette in the last week); live in the catchment area
of the participating NHS site; and are able to understand
and speak English in order to provide verbal telephone
consent and follow-up smoking status.
Intervention
Control group women will receive the offer of usual,
local SSS support.
Intervention group women will receive the same offer
of usual, local SSS support. In addition, they will be of-
fered financial incentives up to £400 to engage with local
SSS and set a quit date, and remain abstinent at each
follow-up point throughout pregnancy. The incentives
will be in the form of Love2Shop gift cards that can be
redeemed in a wide variety of UK shops, none of which
currently sell cigarettes. The incentive rewards structure
is shown in Fig. 2.
Adherence with intervention
Women allocated to the intervention group will have the
opportunity to receive shopping vouchers at four key
time points in the trial, dependent on their smoking sta-
tus. Consequently, adherence will be assessed by consid-
ering distribution and receipt of shopping vouchers,
which will be confirmed by Royal Mail signature.
Outcomes
Primary outcome
The primary outcome is cotinine/anabasine-verified ab-
stinence from smoking for at least 8 weeks towards the
end of pregnancy at 34–38 weeks gestation. The propor-
tion of abstinent women will be compared between the
intervention and control groups.
Secondary outcomes
Secondary outcomes include other key smoking cessa-
tion, child, health economic and process endpoints, and
focus on the difference between the intervention and
control groups regarding the following:
1. Proportion of women who engage with SSS (locally
defined) and set a quit date
2. Proportion of women with biochemically validated
(CO) self-reported abstinence from smoking for at
least 14 days at 4 weeks after quit date
Fig. 2 Incentive and participation rewards structure. CO carbon monoxide, SSS Stop Smoking Services
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3. Proportion of women with cotinine/anabasine-
verified self-reported point abstinence from smok-
ing for at least 8 weeks at 6 months post-partum
4. Proportion of women with cotinine/anabasine-
verified self-reported continuous abstinence from
smoking from late pregnancy to 6 months post-
partum
5. Mean difference in birth weight
6. Cost-effectiveness: incremental cost per late
pregnancy quitter and cost per quality-adjusted life
year (QALY) gained over the trial time horizon and
lifetime
7. Process evaluation: barriers and facilitators to trial
recruitment and future implementation of
incentives in practice
Data for the primary outcome and secondary out-
comes 1, 2 and 5 will be combined with data from the
feasibility trial in a meta-analysis, as described in ‘Statis-
tical methods’.
Sample size and recruitment
The sample size for this phase III trial is 940 pregnant
smokers. This was calculated on the basis of the primary
outcome. A total of 940 participants (470 in each group)
will detect a clinically significant doubling of the
cotinine-validated quit rate from 7% with usual care
alone to at least 14% with usual care plus the offer of fi-
nancial voucher incentives, with 90% power at the 5%
significance level allowing 15% loss to follow-up.
Eligible pregnant smokers will be enrolled over a 26-
month period from February 2018 to March 2020.
Recruiting for 18 months would have allowed all partici-
pants to be followed up to the secondary outcome point
6 months after birth. Recruiting for 26 months (includ-
ing a 3-month funded extension from CRUK—see Fund-
ing for confirmation) has allowed an additional 8
months with recruitment slower than expected whilst
allowing the first 75% of participants recruited to be
followed up to the secondary outcome point 6 months
after birth. This compromised 6-month post-partum
follow-up was agreed with the funders, the ethics com-
mittee and the sponsor prior to the study start in Sep-
tember 2017.
Allocation and blinding
Enrolment and randomisation will be performed over
the telephone by GCP-trained call centre staff at the
Database Management Company (Trial Contact Centre
(TCC)) once the women’s contact details and eligibility
data have been submitted to the secure online trial data-
base by research staff. All calls will be audio-recorded
and information obtained during the call entered directly
into the database. After obtaining informed consent and
baseline data, TCC staff will then press the on-screen
button to randomise women and inform them of their
group allocation. TCC staff will not be able to influence
or predict the random allocation which is integrated into
the database.
The random allocation sequence will be generated by
York Trials Unit. Women will be allocated 1:1 to either
the intervention or the control group using randomly
varying permuted block sizes with no stratification fac-
tors. In addition, a random date between 34 and 38
weeks gestation for each pregnancy will be generated as
the date for primary outcome data collection. This date
will be concealed from both the TCC staff and the
women.
It will not be possible to blind women or research
nurses to group allocation. The TCC staff responsible
for ascertaining the primary outcome measure of self-
reported smoking status in late pregnancy (corroborated
by saliva cotinine measurement collected by a research
nurse) will, however, be blind to allocation. Women will
be asked not to disclose their group status during the
follow-up telephone call with the TCC. The statistician
conducting analyses will have no contact with women
but will not be blind to treatment allocation.
Participant timeline and data collection
The trial consists of an intervention phase between 6
and 38 weeks gestation with five assessment points and
follow-up to 6 months post-partum. The total study
period for each participant will be 42–62 weeks
dependent on gestation at enrolment and timing of pri-
mary outcome assessment in late pregnancy (rando-
mised between 34 and 38 weeks gestation). See Fig. 1 for
an overview of the study design and measurement time
points, and Fig. 3 for the schedule of assessment and
data collection.
Identification and recruitment of participants
Information about the trial will be displayed in appropri-
ate clinical areas. Following antenatal assessment, preg-
nant smokers referred to SSS will be assessed for
eligibility by local SSS or trial research staff. During their
first routine contact with SSS, eligible women will be
given information about the trial. Those who are inter-
ested in taking part will be asked to give verbal permis-
sion for further trial contact and for personal details to
be passed to the TCC to allow informed telephone con-
sent. The SSS will then continue with usual care and
follow-up. If necessary (depending on trial information
provided during first routine SSS contact), local research
staff will telephone women to further discuss the trial
prior to the scheduled consent call. On receipt of per-
sonal details at the TCC, a letter and a participant infor-
mation sheet (PIS) will be automatically sent to women
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by post. Three days after this, an alert will be sent to
those women who agreed to text message contact to re-
mind them of the 0800 number that the TCC will call
them from to discuss the study and obtain consent.
Consent and randomisation
At least 5 days after posting the PIS, the TCC will con-
tact women to undergo formal consent procedures.
Telephone contact will be attempted on a minimum of
three and a maximum of eight occasions, where possible,
at the time slot preferred by the client—weekday am/
pm/evening or weekend am/pm—after which no further
attempts at enrolment will be made. At the start of the
consent call, call handlers will confirm eligibility and re-
ceipt of the PIS. Those who report not having received
the PIS will be given the option of a verbal summary or
to have another copy sent to them and called back in a
few days. On proceeding, 15 consent questions will fol-
low, six of which women must answer and accept to par-
ticipate in the trial. These include consenting to access
to hospital records where appropriate to the trial. One
of the remaining nine questions will ask women to con-
sent to trial staff accessing ‘left-over blood’ from routine
samples collected in late pregnancy. The consent form is
shown as backmatter.
After giving informed consent, women will be asked
baseline questions measuring the level of addiction to
cigarettes (Fagerström Test for Cigarette Dependence
[32]), partner smoking, quality of life (EQ-5D-5L [33]),
household income and use of nicotine alternatives (e.g.
NRT or electronic cigarettes). At the end of the tele-
phone call, women will be randomised and informed of
their group allocation and an automated study pack
(copy of consent form showing group allocation and
PIS) will be sent to women in the post. Audio-
recordings of the consent process will be stored in ac-
cordance with Good Clinical Practice guidelines.
Follow-up 1: SSS engagement
After women have consented and been informed of their
group allocation, trial research staff will contact their
local SSS to ascertain whether women attended a first
appointment with an SSS advisor and set a quit date.
This information will be entered into the trial database
for both control group and intervention group women.
A £50 voucher will automatically be dispatched to inter-
vention group women who attended and set a quit date.
Follow-up 2: 4 weeks post quit date
For those women who engaged with the SSS and set a
quit date, trial research staff will contact their local SSS
4 weeks after this quit date to obtain their smoking sta-
tus in the last 2 weeks and CO breath test result as re-
corded by the SSS. Where a breath test result is not
available from the SSS trial, research nurses will collect
this directly from the woman for the incentives group to
Fig. 3 Schedule of assessment and data collection for trial outcomes. 1CO carbon monoxide, E-cig e-cigarette, NRT nicotine replacement therapy,
SSS Stop Smoking Services
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initiate incentive payments. CO breath test results will
be collected for the control group only where these are
available from the SSS in line with national SSS guide-
lines. This information will be entered onto the trial
database. If the CO result is at or below the accepted
level for a non-smoker at the site, a £50 voucher will
automatically be dispatched to women in the incentives
group.
Follow-up 3: 12 weeks post quit date
For those women in the intervention group who were
confirmed quit at 4 weeks, trial research staff will con-
tact their local SSS 8 weeks later to obtain their smoking
status and CO breath test result as recorded by the SSS.
Where this is not available from the SSS trial, research
nurses will collect this directly from the woman. This in-
formation will be entered into the trial database. If the
CO result is at or below the accepted level for a non-
smoker at the site, a £100 voucher will automatically be
dispatched
Follow-up 4: late pregnancy (34–38 weeks gestation)
All women will be followed up at the primary outcome
stage in late pregnancy. Follow-up telephone contact will
be attempted by the TCC at a random date between 34
and 38weeks gestation allocated at the time of initial ran-
domisation. Trial research nurses will review the women’s
notes 1 week prior to the telephone contact to check the
health status of mother and baby and to alert TCC staff to
any adverse events (e.g. miscarriage or stillbirth) that may
require particular sensitivity when conducting follow-up.
TCC staff will be blind to group allocation.
Three attempts will be made by the TCC to contact
women. If no contact is established women will be
followed up by local research staff by telephone, text and
letter. On successful contact, women will be asked ‘Have
you smoked in the last 8 weeks?’ If yes, ‘Have you
smoked more than 5 cigarettes in that time?’ EQ-5D-5L
data [33] and current NRT/electronic cigarette use will
also be collected at this time point.
Self-report of not smoking will be corroborated by co-
tinine estimation on saliva or urine (when saliva collec-
tion cannot be tolerated). Where women are also using
NRT or electronic cigarettes, anabasine assay on urine
will replace cotinine. Cotinine and anabasine will be
assayed by ABS Laboratories Limited. To minimise the
potential for women to ‘game’ the primary outcome, in-
centive payments will be dependent on the CO result,
which is an immediate measure, and not on the cotinine
or anabasine level.
An important aspect of the primary outcome for this
phase III trial is the proportion of women successfully
followed up in both the intervention and control groups.
To minimise loss to follow-up, particularly among
controls, women in both groups will receive Love2Shop
vouchers of £50 and £25 for providing data and saliva/
urine samples where applicable at the primary (late preg-
nancy) and secondary (6 months post-partum) outcome
time points, respectively (Fig. 2). Acceptable levels are
around 90% of participants successfully followed up in
each group.
To assess whether women lost to trial follow-up are
still smoking towards the end of pregnancy and whether
the primary outcome has been ‘gamed’ (saliva cotinine
below the cut-off point but still smoking in late preg-
nancy), residual blood from routine late pregnancy sam-
ples, where available, will be tested.
Follow-up 5: 6 months post-partum
Similar to the late pregnancy follow-up, all women will
be contacted at 6 months after their expected delivery
date to ascertain their smoking status and collect a sal-
iva/urine sample for those women who self-report as
quit. Quit status 6 months after birth will be ascertained
by two sets of questions:
(1) ‘Have you smoked in the last 8 weeks?’ If yes, ‘Have
you smoked more than 5 cigarettes in that time?’
(2) ‘Have you smoked since your baby was born?’ If
yes, ‘Have you smoked more than 5 cigarettes in
total since your baby was born?’
Follow-up procedures (i.e. number of contact at-
tempts, data collection and saliva/urine sample collec-
tion and assay) will be the same as those described for
the late pregnancy follow-up. Biological samples of saliva
and urine will not be available for use by other
researchers.
Birth-related data collection
After the expected date of delivery, research nurses at
each site will collect and input into the trial database
data regarding parity, baby’s birth date and weight.
Data management
The data management process will be run by York Trials
Unit. The protocol was built on the platform from the
phase II trial [34]. This has been improved and updated
by York Trials Unit in conjunction with the central trial
team (DMT, LS and MM) and has been used for sub-
missions for regulatory approval.
The database is a modified version of that used in
CPIT II. York Trials Unit, central trial management in
Glasgow and research staff at one of the recruiting sites
have contributed to the design of the modified version.
Data entry will be completed by trained research staff
at local sites.
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Statistical methods
Statistical analysis will be conducted by York Trials Unit
(AM and AK). All analyses will be carried out using the
intention-to-treat principle unless stated otherwise.
Treatment effect estimates will be presented along with
the corresponding 95% confidence interval, and statis-
tical tests will be two-sided at the 5% level, unless other-
wise stated.
Primary outcome analysis
Primary outcome analysis will be by intention to treat as
the intervention is the offer of a financial incentive to
engage with SSS and quit smoking. Logistic regression
will adjust for maternal age, years of smoking,
deprivation score, level of smoking and site.
Secondary outcome analysis
Engagement with SSS and self-reported smoking status
at 4 weeks will both be analysed using a logistic regres-
sion model adjusting for the same covariates as the pri-
mary analysis. Continuous and point abstinence (i.e.
regardless of whether participants were abstinent in late
pregnancy) outcomes obtained at 6 months post-partum
[28] will be calculated using logistic regression also
adjusting for the same covariates as the primary out-
come analysis. For each of the following covariates, tests
for interaction with the treatment group will be per-
formed: age of mother, years of smoking, deprivation
score and level of smoking. Effects on the length of neo-
natal unit stays will be examined.
Birth weight will be analysed using a linear regression
model adjusting for key prognostic variables including
age, site, height and weight of mother at early pregnancy.
The intention-to-treat estimate will be severely diluted
due to low smoking cessation rates and the ‘per proto-
col’ analysis will be biased by confounding. Conse-
quently, we will also utilise an instrumental variable
approach—complier average causal effect analysis—
which will estimate the true impact of incentive-induced
smoking cessation on birth weight [35].
Differences by subgroup (e.g. site, deprivation, age
group) will be explored and reported as per the CHAMP
guidelines [36].
A meta-analysis including data collected in the feasi-
bility study in Glasgow on 612 participants [24] will be
undertaken.
Missing data
Where there are missing data for the primary outcome
(i.e. smoking status) it will be assumed that women are
continuing to smoke. This assumption will be examined
by testing residual blood samples (taken for other rea-
sons in late pregnancy) for cotinine, as in the feasibility
trial [24]. This assumption will also apply to the 6-
month post-partum secondary outcome of smoking sta-
tus. Other secondary outcomes (e.g. birth weight) are
collected routinely and will have few missing data. Long-
term outcome data collection will be planned from par-
ticipants and offspring to inform additional follow-up
studies.
Economic and process evaluations
An economic evaluation to assess cost-effectiveness of
offering financial incentives in addition to routine SSS
will be undertaken from an NHS perspective. Details are
the subject of an additional protocol paper to be pub-
lished separately.
A process evaluation using a mixed-methods case-
study approach will explore recruitment and assess
‘intervention context fit’. This is essential to understand
both how the trial functions within different SSS and
how applicable and generalisable the findings may be in
terms of future implementation. Full details of the
process evaluation design and methods are reported in
an Additional file 1.
Data monitoring
Data monitoring will be coordinated by York Trials Unit
and includes some self-monitoring at sites (see
backmatter).
Serious adverse events (SAEs) that are related to the
intervention will be documented. It is not anticipated
that the provision of shopping vouchers to women will
be associated with any related SAEs. SAEs in the feasibil-
ity study were primarily due to miscarriages that were
not related to the intervention. For this reason, a separ-
ate Data Monitoring Committee will not be assembled.
Stopping the trial for reasons not related to safety such
as ‘futility because the required sample size cannot be
reached’ will be decided by the Trial Steering Committee.
Data cleaning will be conducted by York Trials Unit (AM)
and the central trial management team in Glasgow (LS).
Discussion
At present, only 10–20% of pregnant smokers take up
the offer of free SSS and only 3–8% quit during preg-
nancy with usual care that includes counselling and
NRT. Modest incentive payments to engage with SSS
and/or to quit smoking may provide a substantial benefit
by decreasing pregnancy and first-infant year health care
costs. If women stay smoke-free, long-term health care
costs will be substantially reduced. The results of this
phase III multi-centre trial will examine the costs and
benefits of providing financial incentive payments for
smoking cessation during pregnancy across the UK. This
evidence will provide information required for NICE to
consider recommending financial voucher incentive
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payments to support pregnant smokers to quit across
the UK at the scheduled 2021 guideline PH26 [15] up-
date Additional file 2.
Trial status
Recruitment opened in February 2018 and will be
complete by the end of March 2020. On 17 Decem-
ber 2019, 837 of 940 participants were enrolled into
the trial.
Current protocol V3.1, 27 September 2018.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-4042-8.
Additional file 1. Mixed methods process evaluation study protocol
[37–40].
Additional file 2. SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents.
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Trial organisation
Trial Steering Committee
The overall scientific aspects of the project will be overseen by a Steering
Committee. The Steering Committee includes an independent chairperson,
the chief investigator, the main statistician, trial management support,
representatives from the major funding bodies—Cancer Research UK and
the Chief Scientist Office—a patient representative and an international
scientist with research interests in smoking cessation during pregnancy.
The responsibility of the Steering Committee is to ensure the scientific
integrity and quality of the project. To achieve this, the specific
responsibilities of the Steering Committee include: maintaining adherence to
the study protocol; approving changes to the study protocol if required;
reviewing quality assurance indicators; monitoring study recruitment and the
overall study timetable; advising, as required, on specific scientific items that
may arise; compliance with legislation; adherence to research governance;
reporting to funders; and approving publication and dissemination
strategies.
The Steering Committee will meet every 6 months.
Trial Management Group
The Trial Management Group comprises the chief and principal investigators
and co-investigators, trial manager and trial management support, trial ad-
ministrator, trial lead research nurse, site research staff representatives, senior
managers from SSS, data manager, statisticians, health economists and quali-
tative researchers, and supports the running of the trial by the Trial Manage-
ment Working Group. Review meetings are being held quarterly.
Trial Management Working Group
The Trial Management Working Group comprises the chief investigator, trial
manager and trial management support, lead research nurse, site research
staff, statistician and qualitative researcher. The responsibilities of the Trial
Management Working Group include: establishing and monitoring
recruitment of participants; distributing and supplying appropriate
documentation for the trial; data collection and management; data entry
and cleaning; data analysis; and organising and providing information for the
Trial Steering Committee.
Data Monitoring Committee
An independent Data Monitoring Committee will not be established as
adverse events related to the financial incentives intervention are not
envisaged and are not being systematically collected.
Database Management Company
The Database Management Company and the trial team have developed
the trial database which sits behind secure firewalls. The database is
accessed by trial staff over a secure password-protected Internet portal. Data
extracts are provided to York Trials Unit who manage the data output. This
database serves as the data coordinating centre and is overseen by York Tri-
als Unit in terms of data management.
The Database Management Company also provide a call centre facility
where trained staff conduct trial consent and perform initial data collection
for both the primary and secondary outcome assessment of self-reported
smoking status near the end of pregnancy and at 6 months after birth.
The Database Management Company subcontract to a fulfilment house for
provision of a secure document fulfilment service to the trial. The fulfilment
house dispatch the trial PIS to potential participants, paper copies of verbally
obtained consent, GP letters and financial voucher incentive payments by
recorded delivery.
NHS Research and Development Greater Glasgow and Clyde
NHS R&D Glasgow is the sponsor for the trial. NHS R&D offices provide
accommodation for the main trial team in Glasgow, Scotland.
York Trials Unit, University of York
York Trials Unit provide trial management support and data management
including data monitoring, statistical analysis and reporting for the study.
Stop Smoking Services
SSS staff are discussing the trial with potential participants and passing
details of those who give permission to the TCC. SSS are providing cost data
for the economic analysis and a sample of SSS staff will be interviewed as
part of the mixed-methods process evaluation.
Publication policy
The primary results of the trial will be published with authorship in relation
to specific participation in the study, with the name order to be presented
by the principal investigators for consideration by the TSC. Suggested
revisions in the order of authors should meet with the approval of the
principal investigators. Publications in specific areas of the study or on
methodological aspects can be led by co-investigators in their area of ex-
pertise subject to approval by the TSC and the principal investigators. The re-
quirements for authorship will follow recommended practice in journal
guidelines.
Confidentiality
Encryption defined by NHS GG&C security management is in place to pass
data for potential participants from SSS to the Database Management
Company managed trial database and call centre. The Database
Management Company has a long history of managing government-related
services and is able to demonstrate their commitment to data security and
quality management through their ISO27001 and ISO9001 accreditations and
recent GDPR legislation. Their ISO27001 accredited Information Security Man-
agement Systems demand that all of their systems and processes are main-
tained with confidentiality, integrity and availability of data at the core. In
addition, the Database Management Company is ISO9001 accredited, the
internationally recognised standard for Quality Management Systems. Data
are passed via SFTP encrypted in transit. Regular external audits ensure ad-
herence to ISO9001 and ISO27001 standards.
Data will be analysed by staff at York Trials Unit. During and after data
analysis, participants will be identified by their trial number to ensure
confidentiality.
Site confidentiality will be maintained by anonymising sites. This will allow
the process evaluation to provide important insights regarding barriers and
facilitators to future implementation without causing difficulties at trial sites.
Authors’ contributions
DMT and LB conceived the study. DMT, LB, DT, FK, MU, KB, PH, FMH and JM
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study and drafting the protocol. KB and NM designed the health economic
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the study. All authors read and approved the final protocol.
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